X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ct-p6 (9) 9
oncology (7) 7
trastuzumab (7) 7
biosimilar (5) 5
humans (5) 5
breast cancer (4) 4
index medicus (4) 4
safety (4) 4
biological products (3) 3
biosimilar pharmaceuticals - therapeutic use (3) 3
chemotherapy (3) 3
herceptin (3) 3
pharmacokinetics (3) 3
trastuzumab - chemistry (3) 3
trial (3) 3
american society (2) 2
antibodies, monoclonal - therapeutic use (2) 2
biosimilar antibody (2) 2
biosimilar pharmaceuticals - chemistry (2) 2
breast neoplasms - drug therapy (2) 2
cancer research (2) 2
clinical-practice guidelines (2) 2
equivalence (2) 2
female (2) 2
herzuma (2) 2
intravenous administration (2) 2
medicine & public health (2) 2
metastatic breast-cancer (2) 2
1st-line treatment (1) 1
adaptive immunity - drug effects (1) 1
administration, intravenous (1) 1
adult (1) 1
analysis (1) 1
animals (1) 1
antibodies (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - pharmacokinetics (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic agents, immunological - administration & dosage (1) 1
antineoplastic agents, immunological - adverse effects (1) 1
antineoplastic agents, immunological - pharmacokinetics (1) 1
area under curve (1) 1
bioequivalence (1) 1
biosimilar pharmaceuticals - administration & dosage (1) 1
biosimilar pharmaceuticals - adverse effects (1) 1
biosimilar pharmaceuticals - pharmacokinetics (1) 1
biosimilar pharmaceuticals - standards (1) 1
breast neoplasms - pathology (1) 1
breast-cancer (1) 1
cancer (1) 1
cancer therapies (1) 1
care and treatment (1) 1
cell cycle (1) 1
cell growth (1) 1
challenges (1) 1
clinical trials (1) 1
clinical trials as topic (1) 1
confidence intervals (1) 1
costs (1) 1
data bases (1) 1
double-blind (1) 1
double-blind method (1) 1
drug approval (1) 1
drug design (1) 1
drug monitoring - methods (1) 1
drugs (1) 1
efficacy (1) 1
europe (1) 1
extrapolation (1) 1
fda approval (1) 1
follow-up (1) 1
g5 countries (1) 1
gastric cancer (1) 1
gastric-cancer (1) 1
healthy volunteers (1) 1
her2 (1) 1
herzumatm (1) 1
immunogenicity (1) 1
infliximab (1) 1
infusion (1) 1
intravenous infusion (1) 1
male (1) 1
males (1) 1
mechanism of action (1) 1
metastasis (1) 1
monoclonal antibodies (1) 1
monoclonal antibody (1) 1
mortality (1) 1
multicenter (1) 1
neoadjuvant chemotherapy (1) 1
neoplasms - drug therapy (1) 1
neoplasms - epidemiology (1) 1
obstetrics & gynecology (1) 1
outcome assessment (1) 1
patents (1) 1
pf-05280014 (1) 1
pharmacology (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 2018, Volume 41, Issue 7-8, pp. 485 - 485
Journal Article
BREAST CARE, ISSN 1661-3791, 2018, Volume 13, Issue 3, pp. 221 - 221
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 2018, pp. 1 - 11
Therapeutic monoclonal antibody biosimilars are expected to help reduce the sizeable economic burden of targeted treatments. Trastuzumab (Herceptin®), a... 
trastuzumab | mechanism of action | breast cancer | gastric cancer | CT-P6 | Biosimilar
Journal Article
British Journal of Cancer, ISSN 0007-0920, 08/2018, Volume 119, Issue 3, pp. 263 - 265
Journal Article
mAbs, ISSN 1942-0862, 05/2018, Volume 10, Issue 4, pp. 547 - 571
The evaluation of analytical similarity has been a challenging issue for the biosimilar industry because the number of lots for reference and biosimilar... 
trastuzumab | statistical analyses | CT-P6 | Herzuma | reference product | biosimilar | Trastuzumab - chemistry | Biosimilar Pharmaceuticals - chemistry | Reference Standards | Biosimilar Pharmaceuticals - standards | Humans
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 3/2018, Volume 81, Issue 3, pp. 505 - 514
Access to trastuzumab, a valuable anti-cancer treatment, can be limited by cost. The primary aim of this study was to evaluate and compare the PK profiles of... 
Medicine & Public Health | Equivalence | CT-P6 | Oncology | Cancer Research | Safety | Pharmacology/Toxicology | Pharmacokinetics | Biosimilar | Trastuzumab | 1ST-LINE TREATMENT | G5 COUNTRIES | FOLLOW-UP | PHASE-II | CLINICAL-PRACTICE GUIDELINES | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | GASTRIC-CANCER | METASTATIC BREAST-CANCER | PHARMACOLOGY & PHARMACY | PLUS ADJUVANT CHEMOTHERAPY | AMERICAN SOCIETY | Trastuzumab - chemistry | Antineoplastic Agents, Immunological - administration & dosage | Antineoplastic Agents, Immunological - pharmacokinetics | Biosimilar Pharmaceuticals - administration & dosage | Double-Blind Method | Outcome Assessment (Health Care) | Area Under Curve | Trastuzumab - pharmacokinetics | Humans | Trastuzumab - adverse effects | Male | Trastuzumab - administration & dosage | Drug Monitoring - methods | Healthy Volunteers | Biosimilar Pharmaceuticals - adverse effects | Administration, Intravenous | Antineoplastic Agents, Immunological - adverse effects | Adaptive Immunity - drug effects | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Therapeutic Equivalency | Antimitotic agents | Biological products | Antineoplastic agents | Analysis | Intravenous administration | Antibodies | Pharmacology | Males | Confidence intervals | Infusion | Randomization | Immunogenicity | Intravenous infusion | Cancer | Index Medicus
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 4/2014, Volume 144, Issue 2, pp. 233 - 239
Journal Article
Future Oncology, ISSN 1479-6694, 08/2018, Volume 14, Issue 19, pp. 1909 - 1919
Trastuzumab is an anti-HER2 monoclonal antibody indicated for the treatment of HER2-overexpressing breast and gastric cancers. Despite its clinical efficacy,... 
trastuzumab | CT-P6 | safety | pharmacokinetics | breast cancer | HER2 | Herzuma | efficacy | biosimilar | EQUIVALENCE | CHALLENGES | CLINICAL-PRACTICE GUIDELINES | TRIAL | ONCOLOGY | HERCEPTIN | METASTATIC BREAST-CANCER | DOUBLE-BLIND | BIOEQUIVALENCE | AMERICAN SOCIETY
Journal Article
Expert Review of Anticancer Therapy, ISSN 1473-7140, 03/2015, Volume 15, Issue 3, pp. 331 - 338
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.